Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


 

Early Release

  • Update: Ongoing Zika Virus Transmission — Puerto Rico, November 1, 2015–July 7, 2016

    July 29, 2016
    The Puerto Rico Department of Health (PRDH) and CDC devised a Zika virus response strategy after the reporting of the first locally acquired case of Zika virus infection in Puerto Rico in December 2015. During November 1, 2015–July 7, 2016, a total of 23,487 persons with suspected cases of Zika virus disease infection or Guillain-Barré syndrome or who were pregnant but asymptomatic were evaluated by PRDH and CDC Dengue Branch; 5,582 (24%) confirmed and presumptive positive Zika virus cases were identified.

Current Weekly

More

Recommendations and Reports

  • U.S. Medical Eligibility Criteria for Contraceptive Use, 2016

    July 29, 2016
    The 2016 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by women and men who have certain characteristics or medical conditions. Notable updates since the 2010 U.S. MEC include the addition of recommendations for women with cystic fibrosis, women with multiple sclerosis, and women receiving certain psychotropic drugs or St. John’s wort; revisions to the recommendations for emergency contraception, including the addition of ulipristal acetate; and revisions to the recommendations for postpartum women; women who are breastfeeding; women with known dyslipidemias, migraine headaches, superficial venous disease, gestational trophoblastic disease, sexually transmitted diseases, and human immunodeficiency virus; and women who are receiving antiretroviral therapy. These recommendations are a companion document to the CDC U.S. Selected Practice Recommendations for Contraceptive Use, 2016.


    U.S. Selected Practice Recommendations for Contraceptive Use, 2016

    July 29, 2016
    The 2016 U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR) addresses common issues regarding initiation and use of specific contraceptive methods. The information in this report updates the 2013 U.S. SPR. Major updates include 1) revised recommendations for starting regular contraception after the use of emergency contraceptive pills and 2) new recommendations for the use of medications to ease insertion of intrauterine devices. These recommendations are a companion document to the CDC U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.

Surveillance Summaries

  • Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance —The Gonococcal Isolate Surveillance Project,27 Sites, United States, 2014

    July 15, 2016
    Gonorrhea is the second most commonly reported notifiable disease in the United States. Prevention of sequelae and of transmission to sexual partners relies on prompt detection and effective treatment. However, treatment has been compromised by the absence of routine antimicrobial susceptibility testing in clinical care and evolution of antimicrobial resistance to the antibiotics used to treat gonorrhea. Dual therapy with ceftriaxone plus azithromycin is the only recommended gonorrhea treatment, and the potential threat of cephalosporin-resistant gonorrhea is a cause for concern. This report presents comprehensive surveillance data from the Gonococcal Isolate Surveillance Project and describes gonococcal antimicrobial susceptibility patterns in the United States during 2000–2014. Antimicrobial susceptibility surveillance data can be used to develop national treatment recommendations, set research and prevention priorities, and communicate best treatment practices to health care providers.

Supplements

Notifiable Diseases

Top